Dimeric Peptides Targeting EphA2 Receptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for targeting the EphA2 receptor face challenges in achieving specific binding and modulation due to the high conservation of the ATP binding site among kinases and the large size of the ephrin-binding pocket, leading to non-selective interactions and low potency of peptides.
Innovation Solution
Development of dimeric peptides that bind to the ephrin-binding pocket of EphA2 with improved affinity, incorporating modifications such as biotinylation and specific amino acid sequences to promote receptor autophosphorylation and oligomerization, enabling selective modulation of EphA2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptides are designed to bind to the ATP binding site of EphA2, then kinase activity can be inhibited, but selectivity is poor due to high conservation of the ATP binding site among kinases
Solution Approach 1:
The invention extracts the binding function from the conserved ATP site and relocates it to the ephrin-binding pocket, which is less conserved across kinase families. This allows selective targeting of EphA2 while maintaining kinase inhibition capability.
Solution Approach 2:
The peptide acts as an intermediary by binding to the ephrin-binding pocket rather than directly competing with ATP at the conserved active site. This indirect binding mechanism achieves both selectivity and functional inhibition.
2Adaptability or versatility
If peptides are designed to bind to the ephrin-binding pocket of EphA2, then selectivity can be improved, but binding affinity and potency remain low due to the large size of the binding pocket
Solution Approach 1:
The large ephrin-binding pocket is segmented into smaller sub-pockets or binding regions. The peptide is designed to occupy specific sub-regions within the larger pocket, creating multiple focal interaction points that collectively enhance binding affinity while maintaining selectivity.
Solution Approach 2:
The peptide introduces local chemical features (such as specific amino acid side chains or functional groups) that form strong localized interactions with key residues in the ephrin-binding pocket, compensating for the overall large size of the binding site.
3Device complexity
If monomeric peptides are used to target EphA2, then simplicity is maintained, but potency is insufficient due to inability to effectively induce receptor oligomerization
Solution Approach 1:
Two monomeric peptide units are merged into a single dimeric structure through a linker. This dimeric configuration enables the peptide to simultaneously engage multiple EphA2 receptors, effectively inducing receptor oligomerization and enhancing potency while maintaining relatively simple overall architecture.
Solution Approach 2:
The transition from monomeric to dimeric peptide represents a dimensional change in the ligand structure. This structural evolution enables the peptide to interact with EphA2 receptors in a bivalent manner, adding a new dimension of binding capability that promotes receptor clustering and signaling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dimeric peptides exhibit nanomolar potency and specificity for EphA2, effectively promoting receptor activation and downstream signaling, and can be used to treat various pathological conditions including cancer and inflammation.
Implementation Method 1
dimeric peptides that bind to the ephrin-binding pocket of EphA2 with improved affinity
Data Source
AI summary
Disclosed herein are methods and compositions engineered to modulate ephrin type-A receptor 2 (EphA2), including novel compositions comprising one or more dimeric peptide units that binds to a EphA2, wherein the dimeric peptide comprises two or more homologous sequences or fragments thereof, wherein the two or more homologous sequences or fragments thereof, individually, comprise one or more binding sites for the EphA2 with unexpectedly high specificity and binding affinity. The compositions described herein can be attenuated to treat subjects suffering from diseases and/or conditions.